GlaxoSmithkline or GSK finally takes its place today among the world's top drug companies. The $167.58 billion merger of Glaxo Wellcome and SmithKline Beecham will create a pharmaceuticals giant with nearly 19 billion of sales and a market value of $168.02 billion. Its sales force will outgun competitors in most of the 60 countries in which it operates. Only Pfizer of the US, which this year gobbled up Warner-Lambert for $90 billion will be bigger. Along with Pfizer, GSK will have about a 7 per cent share of the global drugs market. That leaves a chasing pack of companies, Merck of the US, Novartis of Switzerland and AstraZeneca of the UK, with about 4.5-5 per cent.